NASDAQ:EIKN Eikon Therapeutics Q3 2026 Earnings Results & Report $4.83 -0.34 (-6.50%) As of 02:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Eikon Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$1.59 versus the -$1.74 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call6:30 AM ET Eikon Therapeutics EPS ResultsActual EPS-$1.59Consensus EPS -$1.74Beat/MissBeat by +$0.15One Year Ago EPSN/AEikon Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eikon Therapeutics Q3 2026 Earnings FAQ Did Eikon Therapeutics beat earnings estimates for Q3 2026? Eikon Therapeutics (NASDAQ:EIKN) reported earnings of -$1.59 per share for Q3 2026, beating the consensus estimate of -$1.74. The report was announced on Thursday, November 12, 2026. Eikon Therapeutics Earnings HeadlinesEikon Therapeutics, Inc. Announces Clearance To Proceed With First-In-Human Phase 1/2 Study For Novel Androgen Receptor Antagonist EIK1006 In Advanced Metastatic Prostate CancerNovember 17 at 10:54 AM | marketscreener.comMEikon Therapeutics, Inc. (EIKN) Receives a Buy from Bank of America SecuritiesNovember 17 at 10:54 AM | theglobeandmail.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 19 at 1:00 AM | Decentralized Masters (Ad)Eikon Receives FDA Clearance to Initiate Phase 1/2 Study of EIK1006 for Metastatic Prostate Cancer TreatmentNovember 17 at 10:54 AM | marketscreener.comMEikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate CancerNovember 17 at 10:54 AM | markets.businessinsider.comEikon Therapeutics Announces FDA Clearance of IND for EIK1006 in Advanced Metastatic Prostate CancerNovember 17 at 6:52 AM | quiverquant.comQSee More Eikon Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eikon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eikon Therapeutics and other key companies, straight to your email. Email Address About Eikon TherapeuticsEikon Therapeutics (NASDAQ:EIKN) is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets. Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines. Eikon’s approach combines laboratory research with computational tools to guide the development of potential drug candidates. Its programs are aimed at advancing new treatments, particularly in oncology.View Eikon Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.